Position Papers
The Position Paper series is a compilation of the Policy Research Institute's views on important topics based on the results of our research to date.
Please refrain from reproducing or reprinting the position papers without permission.
-
The Actual State of the Pharmaceutical Industry and Its Social and Economic Contribution
(No. 11: Issued in January 2026) -
Toward Advancement and Value Enhancement of Medical and Pharmaceutical Products Co-Created with Patients
-Patient-Reported Outcome (PRO) Evaluation as a Permanent Part of the Process-
(No.10: Published December 2025) -
Survey on Emerging Biopharma Companies (EBPs) with Developmental Products in Japan
(No. 9: Issued November 2025) -
Survey of EBP-derived drugs in the U.S.
-Biotech vs. small molecule products.
(No.8: Published in July 2025) (No.8: Published in July 2025) -
Report on Survey of Pharmaceutical Companies on Utilization of Public Databases, etc.
From OPIR Views and ActionsNo.75
(No.7: Published in July 2025) -
A Study on the Rules for Calculating NHI Drug Prices to Assess the Value of Pharmaceuticals
- A continuation of Position Paper No. 3 "Challenges for the Valuation System in the Context of Changes in the Value of Pharmaceuticals" - (No. 6, issued in July 2025)
(No. 6: Issued in Feb. 2025) -
Survey of U.S. EBPs that created small molecule drugs
(No. 5: issued December 2024) -
Linking Information for Effective Use of Health and Medical Information
(No. 4: Issued Nov. 2024) -
Challenges for Evaluation Systems in the Transition of the Value that Pharmaceuticals Bring
(No.3: Issued October 2024) -
Understanding the actual situation of drug lag/loss and factor analysis
(No.2: Issued Jul. 2024) -
Development of drug discovery centers centered on top researchers to promote creation of new drugs originating from academia (Under One Roof Cluster)
(No.1: Jul. 2024 issue)